| Bioactivity | TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases[1]. |
| Invitro | TC-G 24 (Compound 24) binds to the ATP binding site of GSK-3β[1].TC-G 24 (1 µM, 4 h) blocks the FBW7α-mediated degradation of TPP1 in human embryonic kidney (HEK) 293T cells[2]. Western Blot Analysis[2] Cell Line: |
| In Vivo | TC-G 24 (Compound 24) (0-15 mg/kg; i.p.; once) significantly raises liver glycogen content in a dose-dependent manner without obvious toxicity and can cross the BBB[1]. Animal Model: |
| Name | TC-G 24 |
| CAS | 1257256-44-2 |
| Formula | C15H11ClN4O3 |
| Molar Mass | 330.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Khanfar MA, et al. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. J Med Chem. 2010 Dec 23;53(24):8534-45. [2]. Lihui Wang, et al. FBW7 Mediates Senescence and Pulmonary Fibrosis through Telomere Uncapping. Cell Metab. 2020 Nov 3;32(5):860-877.e9. |